Philochem AG (a company of the Philogen group) announces Board of Appeal decision on Philochem’s Patent on Production of Encoded Chemical Libraries

Philogen fornisce un aggiornamento sull’analisi ad interim prevista dallo studio di Fase III FIBROSARC che valuta Onfekafusp alfa (L19TNF) in pazienti con Sarcoma dei tessuti molli, in stato avanzato o metastatico, in prima linea.

FIBROSARC (NCT04650984) è uno studio di Fase III che valuta Onfekafusp alfa (L19TNF, noto anche come Fibromun) in combinazione con doxorubicina rispetto al solo utilizzo di doxorubicina come terapia di...

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with first-line advanced or metastatic Soft Tissue Sarcoma

FIBROSARC (NCT04650984) is a Phase III trial evaluating Onfekafusp alfa (L19TNF, also known as Fibromun) plus doxorubicin versus doxorubicin alone as front-line therapy for patients with advanced or metastatic Soft...

Philogen introduce la piattaforma per il Whistleblowing (Direttiva EU 2019/1937)

Philogen S.p.A. adotta un processo di gestione delle segnalazioni di illeciti riguardanti la Società in linea con le previsioni normative introdotte dal D.lgs. 10 marzo 2023, n. 24 (c.d. “Decreto Whistleblowing”)....

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent Authorities

Philochem AG (a company of the Philogen group) announces the completion of central radiolabeling activities for the therapeutic use of OncoFAP-23

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors